New Chinese Weight-Loss Injection Could Challenge Mounjaro
The once-weekly injection also improved blood pressure, blood sugar control and cholesterol in a 567-person JAMA study.
5 Articles
5 Articles
New Chinese Weight-Loss Injection Could Challenge Mounjaro
Internewscast Internewscast An experimental weight-loss injection could emerge as a serious challenger to blockbuster… This Post: New Chinese Weight-Loss Injection Could Challenge Mounjaro first appeared on Internewscast
A new Chinese drug, ribupatide, leads to 17 percent weight loss in 48 weeks, according to research published in the journal JAMA, Health&Me reports. Ribupatide is being developed in China and has not yet been approved for routine use.
The Phase 3 study published in Jama involved 567 Chinese adults with overweight or obesity, without diabetes. Ribupatide, given once a week, achieved significantly higher results than placebo. The post Obesity. A new drug makes you lose up to 17.7% of weight in 48 weeks appeared first on Quotidiano Sanità.
New Chinese Weight-Loss Injection Could Rival Mounjaro
NewsFinale NewsFinale Journal An experimental weekly weight-loss injection could emerge as a rival to popular treatments including Wegovy and Mounjaro, according to new research. In a clinical trial, ribupatide helped participants lose an average of 17.7 per cent of their body weight—nearly one-fifth—in 11 months. Among patients given the highest dose, half lost more than 20 per cent […]
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium




